Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Seaport Therapeutics, a new biotech firm focused on neuropsychiatric disorders, has officially launched with an oversubscribed $100 million in Series A financing. The company, created by the team behind Karuna Therapeutics, which was recently involved in a multibillion-dollar deal, aims to develop novel treatments for neuropsychiatric conditions using a playbook similar to $KRTX and its Glyph technology platform. Daphne Zohar, co-founder of Karuna Therapeutics, will lead Seaport Therapeutics alongside Steve Paul. The launch has attracted attention and backing from Third Rock Ventures (Third RockV), highlighting the industry's interest in innovative approaches to neuropsychiatric diseases.
.@SeaportTx Launches with $100M Series A Seaport Therapeutics has formally launched with an oversubscribed $100 million Series A financing and a focus on developing neuropsychiatric therapies based on its Glyph™ tech platform. Read more: https://t.co/GQezi1gH5c
Excited for @ThirdRockV to be backing Seaport Therapeutics and their mission to bring forward important new medicines to address neuropsychiatric disease. https://t.co/iwWdPwZdjJ
Seaport Therapeutics is taking aim at neuropsychiatric disorders with a playbook similar to what $KRTX used to great success. The field still has many high hurdles to development, as @realJacobBell laid out in his deep dive we published yesterday: https://t.co/gVPKwU0Pur